Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer
Cited by 17
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
|Journal of Thoracic Oncology|2015|682
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
|Scientific Reports|2016|201
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
|Nature Medicine|2025|76
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18